Your browser is no longer supported. Please, upgrade your browser.
ARNA Arena Pharmaceuticals, Inc. monthly Stock Chart
ARNA [NASD]
Arena Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.94 Insider Own0.59% Shs Outstand32.54M Perf Week7.48%
Market Cap490.70M Forward P/E- EPS next Y-3.17 Insider Trans64.11% Shs Float31.64M Perf Month10.88%
Income-23.00M PEG- EPS next Q-0.75 Inst Own36.00% Short Float25.30% Perf Quarter1.21%
Sales120.80M P/S4.06 EPS this Y79.40% Inst Trans-0.60% Short Ratio25.33 Perf Half Y2.59%
Book/sh1.09 P/B13.83 EPS next Y0.60% ROA-12.50% Target Price35.50 Perf Year-16.69%
Cash/sh2.44 P/C6.17 EPS next 5Y- ROE-110.40% 52W Range11.30 - 19.20 Perf YTD6.20%
Dividend- P/FCF- EPS past 5Y35.00% ROI-16.30% 52W High-18.02% Beta1.33
Dividend %- Quick Ratio1.70 Sales past 5Y57.70% Gross Margin87.40% 52W Low39.29% ATR1.00
Employees106 Current Ratio1.90 Sales Q/Q-32.70% Oper. Margin-15.30% RSI (14)60.21 Volatility10.79% 6.62%
OptionableYes Debt/Eq2.42 EPS Q/Q-1.50% Profit Margin-19.10% Rel Volume2.81 Prev Close15.08
ShortableYes LT Debt/Eq2.29 EarningsAug 08 AMC Payout- Avg Volume316.15K Price15.74
Recom2.40 SMA2011.70% SMA5017.37% SMA2006.25% Volume494,756 Change4.37%
Jun-27-17Initiated Citigroup Buy $23
May-19-17Initiated Leerink Partners Outperform $5
Sep-15-16Initiated FBR & Co. Outperform $6
Mar-01-16Reiterated RBC Capital Mkts Sector Perform $2 → $1.50
Nov-11-15Reiterated RBC Capital Mkts Sector Perform $5 → $2
Oct-28-15Reiterated WallachBeth Buy $6 → $4
May-12-15Reiterated WallachBeth Buy $8 → $6
Jan-23-15Initiated RBC Capital Mkts Sector Perform $5
Aug-07-14Reiterated WallachBeth Buy $9 → $8
Nov-15-13Initiated WallachBeth Buy $9
Oct-03-13Initiated Cowen Market Perform $4.50
Oct-25-10Reiterated Barclays Capital Underweight $3 → $2
Sep-20-10Reiterated UBS Neutral $7 → $2
Sep-17-10Downgrade Davenport Buy → Neutral
Sep-14-10Downgrade Barclays Capital Equal Weight → Underweight $4 → $3
Aug-23-10Reiterated UBS Neutral $3.50 → $7
Jul-16-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform $1
Jul-02-10Reiterated UBS Buy $40 → $38
Feb-04-10Upgrade Rodman & Renshaw Mkt Underperform → Mkt Perform
Dec-17-09Initiated Jefferies & Co Hold $4
Jun-26-17 10:16AM  Edited Transcript of ARNA earnings conference call or presentation 9-May-17 8:30pm GMT Thomson Reuters StreetEvents
Jun-23-17 09:04AM  Better Know a Marijuana Stock: Arena Pharmaceuticals Motley Fool -8.09%
Jun-22-17 08:48AM  Why Arena Pharmaceuticals (ARNA) Could Be Positioned for a Surge Zacks
08:30AM  Strength Seen in Arena Pharmaceuticals (ARNA): Stock Up 5.4% Zacks
Jun-16-17 03:23PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : June 16, 2017 Capital Cube
08:36AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARNA-US : June 16, 2017 Capital Cube
08:00AM  Biotech Industry Showing Signs of a Revival in 2017: Today's Research on Adamis Pharmaceuticals and Arena Pharmaceuticals Accesswire
Jun-15-17 08:30AM  Arena Pharmaceuticals to Present at JMP Securities Life Sciences Conference PR Newswire -6.67%
Jun-14-17 04:01PM  Arena Pharmaceuticals Announces Shareholders and Board of Directors Approve Reverse Stock Split PR Newswire
09:59AM  Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 Capital Cube
08:30AM  Arena Pharmaceuticals Appoints Jennifer Jarrett to Board of Directors PR Newswire
07:02AM  Why Is Arena (ARNA) Up 15.1% Since the Last Earnings Report? Zacks
Jun-01-17 08:30AM  Arena Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference June 9th PR Newswire +6.15%
May-26-17 08:27AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARNA-US : May 26, 2017 Capital Cube
May-24-17 10:38AM  5 Reasons Why VIVUS (VVUS) Stock Should Be in Your Portfolio Zacks
May-23-17 08:09AM  2 Marijuana Stocks That Rocketed Higher by a Double-Digit Percentage Last Week Motley Fool
May-22-17 09:47AM  Can This Struggling Biotech Become the Next Great Marijuana Stock? Motley Fool
08:00AM  Today's Research Reports on Biotech Stocks to Watch: Arena Pharmaceuticals and GlycoMimetics Accesswire
May-19-17 05:05PM  Here's Why Arena Pharmaceuticals Rose as Much as 18.3% Today Motley Fool +15.65%
May-18-17 08:30AM  Arena Pharmaceuticals to Host Key Opinion Leader Event on Pulmonary Arterial Hypertension (PAH) on May 25 in New York City PR Newswire
May-16-17 04:30PM  Arena Pharmaceuticals to Present Phase 1 Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at the American Thoracic Society 2017 International Conference PR Newswire
May-11-17 08:56AM  Edited Transcript of ARNA earnings conference call or presentation 9-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-10-17 10:08AM  Arena Pharmaceuticals (ARNA) Posts Q1 Loss, Revenues Down Zacks -7.75%
May-09-17 05:12PM  Arena Pharmaceuticals reports 1Q loss Associated Press +5.74%
04:01PM  Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2017 Financial Results PR Newswire
01:15PM  Investor Network: Arena Pharmaceuticals, Inc. to Host Earnings Call Accesswire
May-04-17 10:32AM  Arena Pharmaceuticals (ARNA) Q1 Earnings: What's in Store? Zacks -6.02%
May-02-17 08:30AM  Arena Pharmaceuticals to Release First Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, May 9, 2017 PR Newswire
Apr-21-17 04:01PM  Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares PR Newswire
Apr-19-17 02:51PM  Arena Pharmaceuticals, Inc. Value Analysis (NASDAQ:ARNA) : April 19, 2017 Capital Cube
09:37AM  Arena Pharma (ARNA) Down After Underwritten Public Offering Zacks
07:30AM  Biotech Industry Outperforming Major Indexes in 2017: Today's Research Reports on Arena Pharmaceuticals and Cytokinetics Accesswire
02:57AM  Why Is Arena Pharmaceuticals (ARNA) Down 11.3% Since the Last Earnings Report? Zacks
Apr-18-17 12:52PM  Arena Takes a Beating After Lackluster Secondary, Cytokinetics Pops: Biotech Movers TheStreet.com -13.51%
11:05AM  Why Arena Pharmaceuticals Stock Is Getting Hammered Today Motley Fool
10:35AM  Arena Pharmaceuticals Sinks After Announcing Secondary Offering 24/7 Wall St.
08:31AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : April 18, 2017 Capital Cube
Apr-17-17 10:15PM  Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock PR Newswire
08:30AM  Arena Pharmaceuticals Announces Multiple Presentations at ASPET 2017 at Experimental Biology PR Newswire
Apr-11-17 06:00AM  The State of Play in Axovant Sciences Investopedia
Apr-10-17 03:48PM  Why Arena Pharmaceuticals Stock Slimmed Down in March Motley Fool
Apr-07-17 03:50PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : April 7, 2017 Capital Cube
Apr-06-17 09:11AM  New Strong Sell Stocks for April 6th Zacks
Mar-28-17 09:30AM  Today's Research Reports on Biotech Stocks to Watch: Arena Pharmaceuticals and Immunomedics Accesswire
08:07AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : March 28, 2017 Capital Cube
Mar-27-17 03:49PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : March 27, 2017 Capital Cube
08:30AM  Arena Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference on April 4th PR Newswire
Mar-20-17 09:01AM  Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Capital Cube
08:30AM  Arena Pharmaceuticals Appoints Dr. Preston Klassen, M.D., M.H.S. as Executive Vice President, Research and Development and Chief Medical Officer PR Newswire
Mar-18-17 01:04PM  ARENA PHARMACEUTICALS INC Financials
Mar-17-17 10:05AM  Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: 2016 By the Numbers : March 17, 2017
Mar-15-17 02:36PM  How to Trade Wednesday's Most Active Stocks: Lloyds, Arena Pharma, MSCI and More TheStreet.com +12.68%
01:28PM  Why Arena Pharmaceuticals Stock Is Surging Higher Today Motley Fool
12:10PM  Wednesdays Biggest Biopharma Movers 24/7 Wall St.
11:54AM  Arena Pharmaceuticals (ARNA) Posts Q4 Earnings, Revenues Up
11:16AM  7 Most Popular Diet Pills That Work Fast Without Exercise at Insider Monkey
09:32AM  Biotech Premarket Movers: Arena, Immunomedics, Aralez
08:12AM  ARENA PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
Mar-14-17 10:06PM  Edited Transcript of ARNA earnings conference call or presentation 14-Mar-17 8:30pm GMT
04:22PM  Arena Pharmaceuticals beats 4Q profit forecasts
04:10PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:01PM  Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results PR Newswire
07:07AM  Q4 2016 Arena Pharmaceuticals Inc Earnings Release - After Market Close
Mar-13-17 09:00AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : March 13, 2017
Mar-09-17 10:48AM  10 Best Performing Weight Loss Companies And Their Programs at Insider Monkey
Mar-08-17 04:30PM  Arena Pharmaceuticals to Present at the 27th Annual Oppenheimer Healthcare Conference PR Newswire
09:30AM  Biotech's Fall as President Trump to Address Pricing Concerns: Today's Research Reports on Arena Pharmaceuticals and Merrimack Pharmaceuticals Accesswire
Mar-06-17 04:30PM  Arena Pharmaceuticals to Provide Corporate Update and Release Fourth Quarter and Full-Year 2016 Financial Results on Tuesday, March 14, 2017 GlobeNewswire
Feb-27-17 08:21AM  Arena Pharmaceuticals (ARNA) Q4 Earnings: What to Expect? +6.80%
Feb-22-17 08:14AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARNA-US : February 22, 2017
Feb-14-17 09:02AM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
08:30AM  Arena Pharmaceuticals Appoints Three New Members to Board of Directors PR Newswire
Feb-09-17 08:30AM  Arena Pharmaceuticals Announces Three Upcoming Presentations at the 12th Congress of European Crohn's and Colitis Organisation - Inflammatory Bowel Diseases 2017 PR Newswire
Jan-30-17 07:22AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : January 30, 2017
Jan-13-17 08:25AM  Why Arena Pharmaceuticals Stock Sank in 2016 at Motley Fool
Jan-11-17 03:24PM  VIVUS Licenses Rights to PAH Drugs from Selten Pharma
Jan-09-17 06:07PM  Puma (PBYI) Expands Study Cohort for Lead Candidate PB272
08:10AM  Vertex Pharma Issues Disappointing 2017 Orkambi Outlook
Jan-06-17 04:48PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure
10:40AM  Arena Pharmaceuticals Dumps Belviq Weight Loss Drug at Investopedia
08:43AM  Genocea Stock Up on Positive Genital Herpes Infections Data
08:32AM  Biogen Licenses Amunix's XTEN Technology for Factor IX Drug
Jan-05-17 10:37AM  Arena, Eisai Modify Marketing & Supply Agreement for Belviq
09:38AM  Evoke Diabetic Gastroparesis Drug Gimoti Positive in Phase III
08:16AM  Allergan (AGN) Liletta sNDA Accepted for Review in the U.S.
08:07AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : January 5, 2017
Jan-04-17 09:01PM  Eisai Acquires All Global Development and Marketing Rights for Chronic Weight Management Treatment Lorcaserin ACN Newswire
04:23PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex
04:05PM  Arena Pharmaceuticals and Eisai Amend Marketing and Supply Agreement for BELVIQ Globally PR Newswire
09:43AM  Clovis Declares Pricing of Upsized Offering of Common Stock
08:33AM  Allergan Natrelle Inspira Breast Implants Approved in the U.S.
Jan-03-17 08:53AM  Is Vertex Pharma (VRTX) Poised for a Turnaround in 2017?
Dec-27-16 10:17AM  Arena Pharmaceuticals, Inc. Value Analysis (NASDAQ:ARNA) : December 27, 2016
Dec-26-16 07:29AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : December 26, 2016
Dec-19-16 01:30PM  Eisai and Arena Pharmaceuticals Announce Regulatory Approval of BELVIQ® (lorcaserin HCl) in Brazil PR Newswire
12:58PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : December 19, 2016
Dec-18-16 02:27PM  Is Arena Pharmaceuticals, Inc. (ARNA) A Good Stock To Buy? at Insider Monkey
07:35AM  Tax-Loss Selling: 3 Stocks to Dump Right Now at Motley Fool
Dec-13-16 08:30AM  Arena Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-08-16 12:12PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : December 8, 2016
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The company's proprietary investigational clinical programs include etrasimod (APD334), which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Munshi AmitPresident and CEOMay 12Buy1.1925,00029,75076,875May 15 08:04 AM
Munshi AmitPresident and CEOApr 26Buy1.4150,00070,50051,875Apr 27 08:06 AM